Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTJS8PY)

• DTT Name: 5-HT 6 receptor (HTR6) DTT Info
• Gene Name: HTR6

Molecule-Related Drug & Molecule List

15 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[1]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[2]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[3]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[3]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[2]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[4]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[5]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[6]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[7]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[8]
11C-GSK-215083	DMQ0RXA	Neurodegenerative disorder	8A20-8A23	Phase 1	[9]
ABT-354	DMWN7D3	Alzheimer disease	8A20	Phase 1	[10]
AVN-322	DMNIVFJ	Alzheimer disease	8A20	Phase 1	[11]
BVT-74316	DMEP321	Obesity	5B81	Phase 1	[12]
PRX-07034	DM5TLAP	Obesity	5B81	Phase 1	[13]

2 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[14]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[14]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AVN 397	DMFCOZL	Alzheimer disease	8A20	Discontinued in Phase 2	[3]
SYN-114	DM4JPLM	Cognitive impairment	6D71	Discontinued in Phase 1	[15]
WAY-181187	DM8SVHI	Anxiety disorder	6B00-6B0Z	Discontinued in Phase 1	[16]

105 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(+/-)-nantenine	DM0L3GE	Discovery agent	N.A.	Investigative	[17]
1-(2-Methoxy-phenyl)-piperazine	DM3M4RA	Discovery agent	N.A.	Investigative	[18]
1-(3-(benzyloxy)-2-methylphenyl)piperazine	DMQ4MUF	Discovery agent	N.A.	Investigative	[19]
1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine	DMX5N3V	Discovery agent	N.A.	Investigative	[20]
1-(phenylsulfonyl)-4-(piperazin-1-yl)-1H-indole	DM7W25U	Discovery agent	N.A.	Investigative	[21]
1-Benzenesulfonyl-3-piperidin-3-yl-1H-indole	DM1N4LK	Discovery agent	N.A.	Investigative	[22]
1-Benzenesulfonyl-3-piperidin-4-yl-1H-indole	DMRA9VG	Discovery agent	N.A.	Investigative	[23]
1-naphthylpiperazine	DM6BIWK	Discovery agent	N.A.	Investigative	[24]
1-phenylthio-N,N-dimethyltryptamine	DM5REQ9	Discovery agent	N.A.	Investigative	[25]
2-(1-(phenylsulfonyl)-1H-indol-3-yl)ethanamine	DM3D8WI	Discovery agent	N.A.	Investigative	[26]
2-(1-benzyl-1H-inden-3-yl)-N,N-dimethylethanamine	DMB5LHA	Discovery agent	N.A.	Investigative	[27]
2-(1-benzyl-1H-indol-3-yl)-N,N-dimethylethanamine	DMML3XI	Discovery agent	N.A.	Investigative	[27]
2-(1-tosyl-1H-indol-3-yl)ethanamine	DMXCID6	Discovery agent	N.A.	Investigative	[26]
2-(1H-indol-3-yl)-N,N-dimethylethanamine	DMR9Q4Y	Discovery agent	N.A.	Investigative	[28]
2-(3-(phenylsulfonyl)-1H-indol-1-yl)ethanamine	DM94B7N	Discovery agent	N.A.	Investigative	[29]
2-(3-benzenesulfonyl)phenyl-1-aminoethane	DM3FBLT	Discovery agent	N.A.	Investigative	[30]
2-(3-phenylthio)phenyl)-1-aminoethane	DM4WOT6	Discovery agent	N.A.	Investigative	[30]
2-(4-(benzenesulfonyl)phenyl)-1-aminoethane	DMDAO5T	Discovery agent	N.A.	Investigative	[30]
2-Benzyl-4-piperazin-1-yl-1H-benzimidazole	DMYGKW5	Discovery agent	N.A.	Investigative	[31]
2-bromo-LSD	DMOYCWU	Discovery agent	N.A.	Investigative	[24]
2-Ethyl-5-methoxy-3-piperidin-4-yl-1H-indole	DMLC8OB	Discovery agent	N.A.	Investigative	[32]
2-methyl-5-HT	DM1S5CB	N. A.	N. A.	Investigative	[33]
3-(phenylsulfonyl)-1-(piperidin-3-yl)-1H-indole	DMSRHLC	Discovery agent	N.A.	Investigative	[34]
3-(phenylsulfonyl)-1-(piperidin-4-yl)-1H-indole	DM9QB0X	Discovery agent	N.A.	Investigative	[34]
3-(phenylsulfonyl)-1-(pyrrolidin-3-yl)-1H-indole	DMVKO5N	Discovery agent	N.A.	Investigative	[34]
4-((1H-indol-1-yl)methyl)benzenamine	DMRWZ6T	Discovery agent	N.A.	Investigative	[35]
4-(1H-Inden-1-ylmethyl)-phenylamine	DMMJI4R	Discovery agent	N.A.	Investigative	[36]
4-(1H-indol-1-ylsulfonyl)benzenamine	DMY5QBF	Discovery agent	N.A.	Investigative	[21]
4-(1H-Indol-3-ylmethyl)-phenylamine	DMK5CJO	Discovery agent	N.A.	Investigative	[36]
4-(2-benzenesulfonylphenyl)piperazine	DMAZ0LV	Discovery agent	N.A.	Investigative	[30]
4-(3-benzenesulfonamidophenyl)piperazine	DMLVZ6O	Discovery agent	N.A.	Investigative	[30]
4-(3-benzenesulfonylphenyl)piperazine	DMG4X13	Discovery agent	N.A.	Investigative	[30]
4-(3-Methyl-indole-1-sulfonyl)-phenylamine	DM67A4U	Discovery agent	N.A.	Investigative	[18]
4-(3H-Inden-1-ylmethyl)-phenylamine	DM3QJVT	Discovery agent	N.A.	Investigative	[36]
4-(4,6-dinitro-1H-indol-1-ylsulfonyl)benzenamine	DMI1598	Discovery agent	N.A.	Investigative	[21]
4-(4-benzenesulfonamidophenyl)piperazine	DMP0G1W	Discovery agent	N.A.	Investigative	[30]
4-(4-benzenesulfonylphenyl)piperazine	DM0DZFX	Discovery agent	N.A.	Investigative	[30]
4-(4-methoxy-1H-indol-1-ylsulfonyl)benzenamine	DMA7LEO	Discovery agent	N.A.	Investigative	[37]
4-(6-methoxy-1H-indol-1-ylsulfonyl)benzenamine	DM3L5I6	Discovery agent	N.A.	Investigative	[37]
4-(Indan-1-ylsulfanyl)-phenylamine	DMHI50W	Discovery agent	N.A.	Investigative	[36]
4-(Indane-1-sulfonyl)-phenylamine	DM201UM	Discovery agent	N.A.	Investigative	[36]
4-(Naphthalene-1-sulfonyl)-phenylamine	DMI5XB1	Discovery agent	N.A.	Investigative	[18]
4-(piperazin-1-yl)-1H-indole	DMM1RCS	Discovery agent	N.A.	Investigative	[21]
4-(piperazin-1-yl)-3-tosyl-1H-indazole	DM1HM3F	Discovery agent	N.A.	Investigative	[38]
4-Indan-1-ylmethyl-phenylamine	DM6YON7	Discovery agent	N.A.	Investigative	[36]
4-Inden-(1E)-ylidenemethyl-phenylamine	DM23E0R	Discovery agent	N.A.	Investigative	[36]
5,6-dichloro-3,4-dihydroquinazolin-2-amine	DMN1S35	Discovery agent	N.A.	Investigative	[39]
5-(4-Methylpiperazin-1-yl)-3-tosyl-1H-indazole	DMNSIF2	Discovery agent	N.A.	Investigative	[38]
5-CT	DM260KD	Discovery agent	N.A.	Investigative	[40]
5-MEO-DMT	DMG0EL7	Discovery agent	N.A.	Investigative	[41]
5-METHOXYTRYPTAMINE	DMARCKD	Discovery agent	N.A.	Investigative	[42]
6-(piperazin-1-yl)-3-tosyl-1H-indazole	DMM9G0J	Discovery agent	N.A.	Investigative	[38]
6-tosyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole	DMVL218	Discovery agent	N.A.	Investigative	[43]
alpha-ergocryptine	DMMPOEK	Discovery agent	N.A.	Investigative	[44]
alpha-methyl-5-HT	DMCAYXF	Discovery agent	N.A.	Investigative	[44]
AMR-SIX-1	DM7WTKJ	Obesity	5B81	Investigative	[45]
BRL-15572	DMM61Y2	Discovery agent	N.A.	Investigative	[46]
bufotenine	DMD1SY9	Discovery agent	N.A.	Investigative	[33]
CHLOROPHENYLPIPERAZINE	DMOA8L2	Discovery agent	N.A.	Investigative	[47]
DIMEBOLIN	DMV8ZQG	Discovery agent	N.A.	Investigative	[48]
DM-1451	DMM0VDK	Discovery agent	N.A.	Investigative	[49]
E-6837	DMJ2P0N	Discovery agent	N.A.	Investigative	[27]
E6801	DM7LGAF	Discovery agent	N.A.	Investigative	[42]
EDMT	DMS3AXK	Discovery agent	N.A.	Investigative	[50]
EMD-386088	DM3AGUQ	Discovery agent	N.A.	Investigative	[32]
fluperlapine	DM9KIPU	Discovery agent	N.A.	Investigative	[51]
lergotrile	DMDV67S	Discovery agent	N.A.	Investigative	[24]
LY 165,163	DM9IU21	Discovery agent	N.A.	Investigative	[24]
m-chlorophenylpiperazine	DMM1J2D	Discovery agent	N.A.	Investigative	[24]
METHIOTHEPIN	DMMC0I7	Discovery agent	N.A.	Investigative	[52]
MPDT	DMYX31S	Discovery agent	N.A.	Investigative	[50]
N,N-diethyl-2-(1H-indol-3-yl)ethanamine	DM0UBI9	Discovery agent	N.A.	Investigative	[41]
N,N-dimethyl-2-(1-tosyl-1H-indol-3-yl)ethanamine	DMYUQDK	Discovery agent	N.A.	Investigative	[35]
N-(3-(2-aminoethyl)phenyl)benzenesulfonamide	DMP8547	Discovery agent	N.A.	Investigative	[30]
N-(3-(3-aminopropyl)phenyl)benzenesulfonamide	DMW59AY	Discovery agent	N.A.	Investigative	[30]
N-(3-(aminomethyl)phenyl)benzenesulfonamide	DMSC862	Discovery agent	N.A.	Investigative	[30]
N-(3-aminophenyl)benzenesulfonamide	DMJ6FP7	Discovery agent	N.A.	Investigative	[30]
N-(4-(2-aminoethyl)phenyl)benzenesulfonamide	DM1V83P	Discovery agent	N.A.	Investigative	[30]
N-phenyl-3-(2-aminoethyl)benzenesulfonamide	DMWH86J	Discovery agent	N.A.	Investigative	[30]
OCTOCLOTHEPIN	DM0UADK	Discovery agent	N.A.	Investigative	[42]
OPC 4392	DMQOJY2	Discovery agent	N.A.	Investigative	[49]
QUIPAZINE	DMPY6IG	Discovery agent	N.A.	Investigative	[47]
Ro-04-6790	DM6H8JM	Discovery agent	N.A.	Investigative	[27]
SB 258585	DM2QJKZ	Discovery agent	N.A.	Investigative	[53]
SB-214111	DMH1CFX	Discovery agent	N.A.	Investigative	[54]
SB-271046	DM5VJAF	Discovery agent	N.A.	Investigative	[19]
SB-357134	DMFTO8R	Discovery agent	N.A.	Investigative	[55]
SB399885	DMFMK89	Discovery agent	N.A.	Investigative	[56]
SEL-73	DMFKE6C	Psychiatric disorder	6E8Z	Investigative	[45]
SEROTONIN	DMOFCRY	Discovery agent	N.A.	Investigative	[52]
SUVN-501	DMT8PKC	Neurological disorder	6B60	Investigative	[45]
SUVN-504	DMZCKDH	Vomiting	MD90	Investigative	[45]
SUVN-507	DM2UMK8	Neurological disorder	6B60	Investigative	[45]
TFMPP	DMAC8TP	Discovery agent	N.A.	Investigative	[24]
WAY-208466	DM9K2LU	Discovery agent	N.A.	Investigative	[29]
WAY-466	DMMOH51	Discovery agent	N.A.	Investigative	[57]
[125I]SB-258585	DMXWZCB	Discovery agent	N.A.	Investigative	[53]
[2-(3-Benzyl-3H-inden-1-yl)-ethyl]-methyl-amine	DMAJCVL	Discovery agent	N.A.	Investigative	[36]
[2-(3-Benzyl-3H-indol-1-yl)-ethyl]-dimethyl-amine	DMU5P8O	Discovery agent	N.A.	Investigative	[58]
[2-(3-Benzyl-indol-1-yl)-ethyl]-dimethyl-amine	DMBTRN6	Discovery agent	N.A.	Investigative	[36]
[2-(3H-Indol-1-yl)-ethyl]-dimethyl-amine	DM1RW4U	Discovery agent	N.A.	Investigative	[58]
[3H]5-CT	DMEAHFZ	Discovery agent	N.A.	Investigative	[45]
[3H]LSD	DM0YJHS	Discovery agent	N.A.	Investigative	[49]
[3H]Ro 63-0563	DM5XSMN	Discovery agent	N.A.	Investigative	[59]
[3H]spiperone	DMWHEV8	Discovery agent	N.A.	Investigative	[47]

References

• [1] Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
• [2] 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
• [3] Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
• [4] PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
• [5] Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
• [6] Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
• [7] The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
• [8] Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
• [9] Radiosynthesis and characterization of 11C-GSK215083 as a PET radioligand for the 5-HT6 receptor. J Nucl Med. 2012 Feb;53(2):295-303.
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035134)
• [11] AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Curr Alzheimer Res. 2017;14(3):268-294.
• [12] Pharmacological targeting of the serotonergic system for the treatment of obesity. J Physiol. 2009 January 1; 587(Pt 1): 49-60.
• [13] Low-dose prazosin in combination with 5-HT6 antagonist PRX-07034 has antipsychotic effects. Can J Physiol Pharmacol. 2015 Jan;93(1):13-21.
• [14] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [15] Lewy bodies. Proc Natl Acad Sci U S A. 2006 February 7; 103(6): 1661-1668.
• [16] Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466.Neuropsychopharmacology.2008 May;33(6):1323-35.
• [17] Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine. Bioorg Med Chem Lett. 2010 Jan 15;20(2):628-31.
• [18] 1-(1-Naphthyl)piperazine as a novel template for 5-HT6 serotonin receptor ligands. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1707-11.
• [19] Synthesis and SAR of tolylamine 5-HT6 antagonists. Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12.
• [20] The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
• [21] Binding of amine-substituted N1-benzenesulfonylindoles at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5298-302.
• [22] Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Nov 1;15(21):4780-5.
• [23] N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2005 Jan 17;15(2):379-83.
• [24] Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993 Mar;43(3):320-7.
• [25] Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies. J Med Chem. 2008 Feb 14;51(3):603-11.
• [26] Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonist. J Med Chem. 2007 Nov 15;50(23):5535-8.
• [27] Indene-based scaffolds. 2. An indole-indene switch: discovery of novel indenylsulfonamides as 5-HT6 serotonin receptor agonists. J Med Chem. 2009 Feb 12;52(3):675-87.
• [28] Dose-response study of N,N-dimethyltryptamine in humans. I. Neuroendocrine, autonomic, and cardiovascular effects. Arch Gen Psychiatry. 1994 Feb;51(2):85-97.
• [29] Novel 1-aminoethyl-3-arylsulfonyl-1H-pyrrolo[2,3-b]pyridines are potent 5-HT(6) agonists. Bioorg Med Chem. 2009 Jul 15;17(14):5153-63.
• [30] Binding of sulfonyl-containing arylalkylamines at human 5-HT6 serotonin receptors. J Med Chem. 2006 Aug 24;49(17):5217-25.
• [31] Benzimidazole derivatives as new serotonin 5-HT6 receptor antagonists. Molecular mechanisms of receptor inactivation. J Med Chem. 2010 Feb 11;53(3):1357-69.
• [32] 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4230-4.
• [33] Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. Neuropharmacology. 1997 Apr-May;36(4-5):713-20.
• [34] 3-(Arylsulfonyl)-1-(azacyclyl)-1H-indoles are 5-HT(6) receptor modulators. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1657-60.
• [35] Further studies on the binding of N1-substituted tryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1691-4.
• [36] Binding of isotryptamines and indenes at h5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2005 Apr 15;15(8):1987-91.
• [37] Binding of methoxy-substituted N1-benzenesulfonylindole analogs at human 5-HT6 serotonin receptors. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3793-6.
• [38] 5-Piperazinyl-3-sulfonylindazoles as potent and selective 5-hydroxytryptamine-6 antagonists. J Med Chem. 2010 Nov 11;53(21):7639-46.
• [39] Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
• [40] Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996 Jan;66(1):47-56.
• [41] Interaction of N1-unsubstituted and N1-benzenesulfonyltryptamines at h5-HT6 receptors. Bioorg Med Chem Lett. 2006 Nov 15;16(22):5832-5.
• [42] Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem. 2005 Mar 24;48(6):1781-95.
• [43] A regiospecific synthesis of a series of 1-sulfonyl azepinoindoles as potent 5-HT6 ligands. Bioorg Med Chem Lett. 2008 Jul 15;18(14):3929-31.
• [44] Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor. J Neurochem. 1998 Nov;71(5):2169-77.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).
• [46] SB-216641 and BRL-15572--compounds to pharmacologically discriminate h5-HT1B and h5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):312-20.
• [47] Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7). J Med Chem. 2003 Jul 3;46(14):2795-812.
• [48] 8-Sulfonyl-substituted tetrahydro-1H-pyrido[4,3-b]indoles as 5-HT6 receptor antagonists. Eur J Med Chem. 2010 Feb;45(2):782-9.
• [49] Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology. 1999 Jun;20(6):612-27.
• [50] 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000 Mar 9;43(5):1011-8.
• [51] Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther. 1994 Mar;268(3):1403-10.
• [52] 5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. J Med Chem. 2010 Mar 25;53(6):2521-7.
• [53] 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. Synapse. 2002 Sep 1;45(3):191-9.
• [54] The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]S... Brain Res. 2002 Apr 26;934(1):49-57.
• [55] Discovery of 3-aryl-3-methyl-1H-quinoline-2,4-diones as a new class of selective 5-HT6 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 15;18(2):738-43.
• [56] SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition ... Eur J Pharmacol. 2006 Dec 28;553(1-3):109-19.
• [57] Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists. J Med Chem. 2005 Jan 27;48(2):353-6.
• [58] Possible differences in modes of agonist and antagonist binding at human 5-HT6 receptors. Bioorg Med Chem Lett. 2004 Sep 6;14(17):4569-73.
• [59] The 5-hydroxytryptamine6 receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum. Mol Pharmacol. 1998 Sep;54(3):577-83.